treatment | Page 56 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

treatment

  1. Home

Swapna Thota, MD

Thota, Swapna
Assistant Professor of Medicine
University of Tennessee

As a physician caring for patients with acute leukemias and related disorders, I have a sustained focus on translational research in hematologic malignancies. Genomic sequencing technology revolutionized our understanding of cancer biology. My research focuses on exploring the dynamic changes of tumor immune microenvironment with clonal evolution of myeloid malignancies. Targeting inflammaging of

Online Profile: 
Assistant Professor

Understanding GVHD

Dr. Catherine Lee will provide a comprehensive overview of chronic and acute graft vs host disease ("GvHD") which is a complication of bone marrow transplant.  While some patients have very mild GvHD, many patients have more severe and long term disease.  Dr. Lee will discuss pre-transplant prevention and post-transplant management of GvHD. 

Catherine Lai, MD, MPH

Lai, Catherine
Associate Professor and Physician Leader of the Leukemia Clinical Research Unit
University of Pennsylvania’s Perelman Center for Advanced Medicine

Dr. Lai's clinical expertise is in Blood and Marrow Transplantation (BMT). She specializes in autologous and allogeneic hematopoietic cell transplants for the treatment of malignant and benign hematologic diseases in adult patients. She conducts her research in the Medicine Division of Hematology/BMT at the Huntsman Cancer Center. 

Online Profile: 
Associate Professor and Physician Leader

Alrizomadlin (APG-115)

Alrizomadlin is an orally administered, selective, small-molecule inhibitor of the MDM2 protein. Alrizomadlin has strong binding affinity to MDM2 and is designed to activate tumor suppression activity of p53 by blocking the MDM2-p53 protein-protein interaction.

Gerard Socie, MD

Socie, Gerard
Head of Hematology
Hospital St. Louis

Gerard Socié, MD, PhD, is the head of the hematology department at Hospital Saint-Louis, APHP. Gerard Socié has a research appointment at the Institut Pasteur -APHP with Dr. Lars Rogge.   His main fields of expertise are transplantation (GvHD),

Online Profile: 
Head of Hematology

Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)

 – With this approval, ULTOMIRIS is the first and only medicine approved in the U.S. to treat children and adolescents with PNH –

– Approval based on interim results from Phase 3 study showing ULTOMIRIS demonstrated complete terminal complement inhibition through 26 weeks –